Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 20:48 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005602 · form4.xml · derivative · entry 5 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,934 Underlying: Common Stock · 263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:48 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 88 | $187.51 | $16,500.88 |
DisclosureSEC source: 0001127602-20-005602 · form4.xml · nonDerivative · entry 4 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,061 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:48 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 316 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005602 · form4.xml · nonDerivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:48 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 71 | $187.51 | $13,313.21 |
DisclosureSEC source: 0001127602-20-005602 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,833 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:48 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005602 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:42 UTC |
KING DAVID PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005600 · form4.xml · derivative · entry 7 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,558 Underlying: Common Stock · 4,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:42 UTC |
KING DAVID PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005600 · form4.xml · derivative · entry 6 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,794 Underlying: Common Stock · 3,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:42 UTC |
KING DAVID PDirector
|
Tax withholdingCommon Stock | 1,894 | $187.51 | $355,143.94 |
DisclosureSEC source: 0001127602-20-005600 · form4.xml · nonDerivative · entry 4 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,392.1345 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:42 UTC |
KING DAVID PDirector
|
Exercise / conversionCommon Stock | 4,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005600 · form4.xml · nonDerivative · entry 3 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,286.1345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:42 UTC |
KING DAVID PDirector
|
Tax withholdingCommon Stock | 1,386 | $187.51 | $259,888.86 |
DisclosureSEC source: 0001127602-20-005600 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,050.1345 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:42 UTC |
KING DAVID PDirector
|
Exercise / conversionCommon Stock | 3,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005600 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,436.1345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:36 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005597 · form4.xml · derivative · entry 3 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:36 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005597 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:30 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005595 · form4.xml · derivative · entry 3 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:30 UTC |
BELINGARD JEAN-LUCDirector
|
Tax withholdingCommon Stock | 123 | $187.51 | $23,063.73 |
DisclosureSEC source: 0001127602-20-005595 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,061 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:30 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005595 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:26 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005593 · form4.xml · derivative · entry 2 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:26 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005593 · form4.xml · nonDerivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:13 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005590 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:13 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005590 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:20 UTC |
Kong GarhengDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005592 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:20 UTC |
Kong GarhengDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005592 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:08 UTC |
Williams R SandersDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005587 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:08 UTC |
Williams R SandersDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005587 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 18:47 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 108 | $181.99 | $19,654.92 |
DisclosureSEC source: 0001127602-20-004811 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300.3565 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 14.7164 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 18:45 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
SaleCommon Stock | 133 | $181.99 | $24,204.67 |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,528.8788 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 37.511 shares acquired on June 28, 2019 and 30.121 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:38 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 297 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004802 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,707 Underlying: Common Stock · 297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:38 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Tax withholdingCommon Stock | 103 | $182.33 | $18,779.99 |
DisclosureSEC source: 0001127602-20-004802 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,291 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:38 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionCommon Stock | 297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004802 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:47 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 297 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004811 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,027 Underlying: Common Stock · 297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:47 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 82 | $182.33 | $14,951.06 |
DisclosureSEC source: 0001127602-20-004811 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408.3565 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 14.7164 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:47 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004811 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490.3565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 14.7164 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:45 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,330 Underlying: Common Stock · 367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:45 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Tax withholdingCommon Stock | 101 | $182.33 | $18,415.33 |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661.8788 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 37.511 shares acquired on June 28, 2019 and 30.121 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:45 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Exercise / conversionCommon Stock | 367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,762.8788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 37.511 shares acquired on June 28, 2019 and 30.121 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:43 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 337 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004807 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,197 Underlying: Common Stock · 337 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:43 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 103 | $182.33 | $18,779.99 |
DisclosureSEC source: 0001127602-20-004807 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,641 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:43 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 337 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004807 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:42 UTC |
KING DAVID PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004806 · form4.xml · derivative · entry 4 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,307 Underlying: Common Stock · 4,220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:42 UTC |
KING DAVID PDirector
|
Tax withholdingCommon Stock | 1,252 | $182.33 | $228,277.16 |
DisclosureSEC source: 0001127602-20-004806 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,923.1345 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 21.7403 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:42 UTC |
KING DAVID PDirector
|
Exercise / conversionCommon Stock | 4,220 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004806 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,175.1345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 21.7403 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:39 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004803 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,370 Underlying: Common Stock · 994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:39 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 295 | $182.33 | $53,787.35 |
DisclosureSEC source: 0001127602-20-004803 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,758 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:39 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004803 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:53 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003962 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:37 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 45,600 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003954 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 Underlying: Common Stock · 45,600 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:37 UTC |
Schechter Adam HDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 10,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003954 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,767 Underlying: Common Stock · 10,520 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:55 UTC |
Williams R SandersDirector
|
GrantRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003964 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 986 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:35 UTC |
Seltz Judith CChief Human Resources Officer
|
GrantNon-qualified Stock Options · Derivative | 3,600 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003953 · form4.xml · derivative · entry 2 Seltz Judith C · CIK 0001791228 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2030-02-03 F3 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:35 UTC |
Seltz Judith CChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003953 · form4.xml · derivative · entry 1 Seltz Judith C · CIK 0001791228 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840 Underlying: Common Stock · 840 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.